Liu YW, Su YW, Ong WK, Cheng TH, Tsai YC
sometimes increases in HDL Liver : Improvements in fatty liver disease (reduced liver fat, improved liver enzymes) Cardiovascular Improvements : Blood Pressure : Significant reductions in systolic and diastolic blood pressure Cardiovascular Events : According to SELECT trial (semaglutide), 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) Heart Function : Improvements in cardiac structure and function markers Physical Function Improvements : Mobility : Improved ability to walk, climb stairs, engage in physical activities Joint Pain : Reduced knee, hip, and back pain from decreased weight-bearing stress Sleep : Improvements in sleep quality
Long-term effects of empagliflozin in patients with chronic kidney disease
We encourage nourishing, sustainable habitsnot restrictive dieting
doi: 10.1016/j.pharmthera.2021.107916